carbohydrate phosphate - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	carbohydrate phosphate	go back to main search page
Accession:	CHEBI:26816	browse the term
Synonyms:	related_synonym:	carbohydrate phosphates

show annotations for term's descendants Sort by:
Rat (1871) Mouse (1872) Human (1915) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (26) Green Monkey (0) Naked Mole-rat (0) All
Genes (1871)

1,2-dioctanoyl-sn-glycero-3-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin-endoperoxide synthase 2

increases expression

dioctanoylphosphatidic acid results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

1-octadec-9-enoylglycero-3-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

lysophosphatidic acid results in increased expression of ACTA2 mRNA
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]

PMID:14769825 PMID:17550345 PMID:20103642

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

arachidonate 5-lipoxygenase

multiple interactions

ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

alkaline phosphatase, biomineralization associated

multiple interactions

[Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

BCAR1 scaffold protein, Cas family member

increases phosphorylation

lysophosphatidic acid results in increased phosphorylation of BCAR1 protein

NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907

G

BCL2, apoptosis regulator

increases expression

lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

complement C5

increases expression

lysophosphatidic acid results in increased expression of HC protein

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

caspase 3

multiple interactions

lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 12

increases expression
multiple interactions

lysophosphatidic acid results in increased expression of CCL12 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein]

NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780

G

C-C motif chemokine ligand 28

multiple interactions
increases expression

3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein]

NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997

G

cellular communication network factor 1

multiple interactions
increases expression

3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein]

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

increases expression
multiple interactions

lysophosphatidic acid results in increased expression of CCN2 protein
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA]
Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]

PMID:15200425 PMID:24706986

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

collagen type I alpha 2 chain

increases expression
multiple interactions

lysophosphatidic acid results in increased expression of COL1A2 mRNA
N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

colony stimulating factor 1

increases expression

lysophosphatidic acid results in increased expression of CSF1 protein

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

C-X-C motif chemokine ligand 12

increases expression
multiple interactions

lysophosphatidic acid results in increased expression of CXCL12 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein]

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 16

increases expression
multiple interactions

lysophosphatidic acid results in increased expression of CXCL16 protein
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein]

NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592

G

C-X-C motif chemokine receptor 1

multiple interactions
decreases expression

lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]
lysophosphatidic acid results in decreased expression of CXCR1 mRNA

NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084

G

diacylglycerol kinase, alpha

multiple interactions

DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]

NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110

G

epidermal growth factor receptor

multiple interactions
increases phosphorylation

GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions
increases phosphorylation

1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions
decreases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA]

PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 More...

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

erythropoietin

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

GATA binding protein 1

multiple interactions

[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]

NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530

G

G protein subunit alpha 13

multiple interactions

GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]

NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774

G

glycophorin A

multiple interactions

lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]

NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
increases expression

L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein

PMID:17919812 PMID:22537771

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heat shock protein family B (small) member 1

multiple interactions
increases phosphorylation

MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

interleukin 1 beta

multiple interactions

IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases secretion

lysophosphatidic acid results in increased secretion of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 cytokine family signal transducer

multiple interactions
increases expression

3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein]

NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936

G

KIT ligand

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

kininogen 1

multiple interactions

KNG1 protein inhibits the reaction [[Wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

laminin subunit alpha 3

increases expression

lysophosphatidic acid results in increased expression of LAMA3 mRNA

NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353

G

laminin subunit beta 3

increases expression

lysophosphatidic acid results in increased expression of LAMB3 mRNA

NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405

G

laminin subunit gamma 2

increases expression

lysophosphatidic acid results in increased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lysophosphatidic acid receptor 1

increases response to substance
multiple interactions

LPAR1 protein results in increased susceptibility to lysophosphatidic acid
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein]

PMID:16224106 PMID:16809448 PMID:25398768

NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895

G

lysophosphatidic acid receptor 3

multiple interactions

Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein

NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357

G

lysophosphatidic acid receptor 5

multiple interactions

Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein

NCBI chr 4:157,870,493...157,883,979
Ensembl chr 4:157,881,796...157,882,950

G

lysophosphatidic acid receptor 6

multiple interactions

lysophosphatidic acid binds to and results in increased activity of LPAR6 protein

NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]

PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]

PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

myelin basic protein

multiple interactions

lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA]

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

matrix metallopeptidase 9

multiple interactions
increases expression

gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases phosphorylation

lysophosphatidic acid results in increased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

myosin light chain 9

increases phosphorylation
multiple interactions

lysophosphatidic acid results in increased phosphorylation of MYL9 protein
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

myosin light chain kinase

affects response to substance

MYLK protein affects the susceptibility to lysophosphatidic acid

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

NFE2 like bZIP transcription factor 2

multiple interactions

LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein
[[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

natriuretic peptide A

multiple interactions
increases expression

Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]

PMID:15081308 PMID:25449040

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

p21 (RAC1) activated kinase 1

increases activity
multiple interactions

lysophosphatidic acid results in increased activity of PAK1 protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; diphenyleneiodonium inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Genistein inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]

NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383

G

phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha

multiple interactions
increases activity

1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]

NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598

G

plasminogen activator, urokinase

multiple interactions
increases expression

gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

phospholipase D1

multiple interactions
increases activity

1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein]

PMID:11243883 PMID:14769825

NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692

G

protein phosphatase 1, regulatory subunit 12A

increases phosphorylation
multiple interactions

lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein
Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein]

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

protein tyrosine kinase 2

increases phosphorylation
multiple interactions

lysophosphatidic acid results in increased phosphorylation of PTK2 protein
[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]
[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]

PMID:10537051 PMID:11792571

NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783

G

protein tyrosine kinase 2 beta

increases phosphorylation

lysophosphatidic acid results in increased phosphorylation of PTK2B protein

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

ras homolog family member A

increases activity
multiple interactions

lysophosphatidic acid results in increased activity of RHOA protein
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]

PMID:15081308 PMID:24587105

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

ras homolog family member C

multiple interactions
increases activity

Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

ribosomal protein S6 kinase B1

increases phosphorylation
multiple interactions

lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein
resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]

PMID:14769825 PMID:17919812

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

transferrin receptor

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

TIMP metallopeptidase inhibitor 1

multiple interactions
increases expression

3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions

TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

increases expression
multiple interactions

[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein
resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

2'-deoxycytosine 5'-monophosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Deoxycytidine Monophosphate]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

2'-deoxyguanosine 5'-monophosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 2'-deoxyguanosine 5'-phosphate]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

2,3-bisphospho-D-glyceric acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADP-ribosylation factor 6

multiple interactions

2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]

NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114

G

bone gamma-carboxyglutamate protein

decreases activity

2,3-Diphosphoglycerate results in decreased activity of BGLAP protein

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

phospholipase D1

decreases activity

2,3-Diphosphoglycerate results in decreased activity of PLD1 protein

NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692

G

steroid sulfatase

multiple interactions

2,3-Diphosphoglycerate inhibits the reaction [Tretinoin results in increased activity of STS protein]

NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402

2,3-bisphosphoglyceric acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADP-ribosylation factor 6

multiple interactions

2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]

NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114

G

bone gamma-carboxyglutamate protein

decreases activity

2,3-Diphosphoglycerate results in decreased activity of BGLAP protein

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

phospholipase D1

decreases activity

2,3-Diphosphoglycerate results in decreased activity of PLD1 protein

NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692

G

steroid sulfatase

multiple interactions

2,3-Diphosphoglycerate inhibits the reaction [Tretinoin results in increased activity of STS protein]

NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402

2-amino-2-deoxy-D-glucopyranose 6-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CCAAT/enhancer binding protein alpha

decreases expression

glucosamine 6-phosphate results in decreased expression of CEBPA protein

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

delta like non-canonical Notch ligand 1

decreases expression

glucosamine 6-phosphate results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

fatty acid binding protein 4

decreases expression

glucosamine 6-phosphate results in decreased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

decreases expression

glucosamine 6-phosphate results in decreased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucosamine 6-phosphate]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

leptin

decreases expression

glucosamine 6-phosphate results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

lipase E, hormone sensitive type

increases expression

glucosamine 6-phosphate results in increased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lipoprotein lipase

decreases expression

glucosamine 6-phosphate results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

peroxisome proliferator-activated receptor gamma

decreases expression

glucosamine 6-phosphate results in decreased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

sterol regulatory element binding transcription factor 1

decreases expression

glucosamine 6-phosphate results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

tumor necrosis factor

decreases expression

glucosamine 6-phosphate results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

2-deoxy-alpha-D-ribose 1-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thymidine phosphorylase

increases abundance

TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

2-deoxy-D-ribofuranose 1-phosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

thymidine phosphorylase

increases abundance

TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

3',5'-cyclic AMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
multiple interactions

Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein
[HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein

PMID:20339114 PMID:20655299

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily C member 4

increases transport
multiple interactions
affects uptake

ABCC4 protein results in increased transport of Cyclic AMP
Probenecid affects the reaction [ABCC4 protein affects the uptake of Cyclic AMP analog]

PMID:11856762 PMID:28587784

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

adenylate cyclase activating polypeptide 1

multiple interactions

[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

adiponectin, C1Q and collagen domain containing

increases abundance

ADIPOQ protein results in increased abundance of Cyclic AMP

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenomedullin

multiple interactions
increases abundance

ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]
ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP

PMID:10374718 PMID:17306419

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adrenoceptor alpha 1B

multiple interactions

ADRA1B protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor beta 1

multiple interactions
increases abundance
affects abundance

[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]
ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP
ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]

PMID:11562432 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
increases chemical synthesis
increases abundance
affects abundance

[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]
ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP
[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]
ADRB2 protein results in increased abundance of Cyclic AMP
ADRB2 protein affects the abundance of Cyclic AMP

PMID:10516654 PMID:10857765 PMID:10952688 PMID:11562432 PMID:12920204 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions
affects abundance

3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP
ADRB3 protein affects the abundance of Cyclic AMP

PMID:10952688 PMID:14730417

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

adenosylhomocysteinase-like 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of AHCYL1 mRNA]

NCBI chr 2:195,294,149...195,328,586
Ensembl chr 2:195,294,153...195,345,815

G

aryl hydrocarbon receptor

multiple interactions
decreases expression

AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA
Cyclic AMP results in decreased expression of AHR protein

PMID:12859982 PMID:32781018

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

alkaline phosphatase, placental

multiple interactions

[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

angiopoietin-like 4

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANGPTL4 mRNA]

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ANK2 mRNA]

NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923

G

aquaporin 3 (Gill blood group)

multiple interactions
increases expression

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 5

multiple interactions

Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein

NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209

G

armadillo-like helical domain containing 4

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ARMH4 mRNA]

NCBI chr15:22,975,895...23,076,986
Ensembl chr15:22,975,895...23,076,949

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

arrestin, beta 2

multiple interactions

[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

activating transcription factor 5

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ATF5 mRNA]

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

arginine vasopressin

multiple interactions

[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

arginine vasopressin receptor 2

multiple interactions
increases abundance

[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP
AVPR2 protein results in increased abundance of Cyclic AMP

PMID:20683494 PMID:33638691

NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989

G

brain-derived neurotrophic factor

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

B-Raf proto-oncogene, serine/threonine kinase

increases activity
multiple interactions

Cyclic AMP results in increased activity of BRAF protein
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein

NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463

G

similar to human chromosome 1 open reading frame 115

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C13H1ORF115 mRNA]

NCBI chr13:96,422,308...96,432,044
Ensembl chr13:96,422,302...96,432,068

G

C1q and TNF related 5

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of C1QTNF5 mRNA]

NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074

G

calcitonin-related polypeptide alpha

increases abundance
multiple interactions

CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP
CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]
Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]

PMID:15297469 PMID:17295025 PMID:17306419 PMID:18463244

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

coactivator-associated arginine methyltransferase 1

multiple interactions
increases phosphorylation

[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter]

NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689

G

cholecystokinin B receptor

multiple interactions

CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP]

NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881

G

C-C motif chemokine ligand 3

multiple interactions

Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cellular communication network factor 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CCN2 mRNA]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin D1

multiple interactions

[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CD3 epsilon subunit of T-cell receptor complex

decreases phosphorylation

Cyclic AMP results in decreased phosphorylation of CD3E protein

NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022

G

CD3 gamma subunit of T-cell receptor complex

decreases phosphorylation

Cyclic AMP results in decreased phosphorylation of CD3G protein

NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147

G

cell division cycle 42

multiple interactions
increases chemical synthesis

[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein]

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein beta

increases response to substance

CEBPB protein results in increased susceptibility to Cyclic AMP

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CF transmembrane conductance regulator

multiple interactions
increases activity

Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides]
CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]
Cyclic AMP results in increased activity of CFTR protein
Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form]

PMID:11786964 PMID:12529251 PMID:12556293 PMID:12612912 PMID:15229107 More...

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

glycoprotein hormones, alpha polypeptide

multiple interactions
affects secretion
increases abundance

[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA
CGA protein affects the secretion of Cyclic AMP
CGA protein results in increased abundance of Cyclic AMP
[CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]

PMID:8404651 PMID:20378682 PMID:21642635 PMID:23071612 PMID:26895433 More...

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

chondroitin sulfate synthase 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CHSY1 mRNA]

NCBI chr 1:119,689,626...119,750,711
Ensembl chr 1:119,686,350...119,750,601

G

cannabinoid receptor 1

multiple interactions

[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]

PMID:10422789 PMID:11730719 PMID:17953657 PMID:27429655

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

multiple interactions

(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]

PMID:17558435 PMID:27429655

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

contactin 1

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA

NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541

G

ceruloplasmin

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CP mRNA]

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element binding protein 1

multiple interactions

[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer]

PMID:12859982 PMID:22676303

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

multiple interactions

CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

corticotropin releasing hormone

multiple interactions

[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]
CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]

PMID:2153673 PMID:20702571

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

corticotropin releasing hormone receptor 1

multiple interactions

[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

C-reactive protein

multiple interactions

Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 3

increases expression

Cyclic AMP results in increased expression of CSF3 protein

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

C-terminal Src kinase

multiple interactions

CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]]

NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292

G

cystatin B

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CSTB mRNA]

NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526

G

cathepsin A

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of CTSA mRNA]

NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215

G

cytochrome P450, family 11, subfamily a, polypeptide 1

increases expression
multiple interactions

Cyclic AMP results in increased expression of CYP11A1 mRNA
Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein
myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]

PMID:25576683 PMID:28668616 PMID:29228121

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

multiple interactions
increases expression

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA]

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions
increases expression

[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein
Cyclic AMP results in increased expression of CYP17A1 mRNA

PMID:23084589 PMID:25576683

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases expression
multiple interactions

Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]

PMID:29228121 PMID:31953017

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer]

PMID:12859982 PMID:32781018

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 51

increases expression

Cyclic AMP results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily B member 1

decreases expression
decreases activity

Cyclic AMP results in decreased expression of CYP7B1 mRNA
Cyclic AMP results in decreased activity of CYP7B1 protein

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

death-associated protein

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DAP mRNA]

NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752

G

D-dopachrome tautomerase

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of DDT mRNA]

NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482

G

DISC1 scaffold protein

multiple interactions

Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein]

NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778

G

dickkopf WNT signaling pathway inhibitor 1

affects response to substance

DKK1 protein affects the susceptibility to Cyclic AMP

NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202

G

dihydrolipoamide dehydrogenase

increases abundance

DLD protein results in increased abundance of Cyclic AMP

NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795

G

discs large MAGUK scaffold protein 4

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA

NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153

G

dopamine receptor D1

multiple interactions

A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]
[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]

PMID:8558425 PMID:15711596

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP]

PMID:11880531 PMID:17958328

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D4

multiple interactions

[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP]

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

E2F transcription factor 2

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

epidermal growth factor receptor

multiple interactions

[Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

multiple interactions

[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

EH-domain containing 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of EHD2 mRNA]

NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783

G

endonuclease domain containing 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENDOD1 mRNA]

NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892

G

enolase 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ENO2 mRNA]

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

erythropoietin

increases expression

Cyclic AMP results in increased expression of EPO protein

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

ERBB receptor feedback inhibitor 1

increases expression

Cyclic AMP results in increased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

estrogen receptor 1

multiple interactions
increases activity

[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein]

PMID:19766106 PMID:20360387

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]

PMID:19766106 PMID:20378682

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

coagulation factor II (thrombin) receptor

multiple interactions

[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

F2R like trypsin receptor 1

multiple interactions

Cyclic AMP promotes the reaction [F2RL1 protein results in increased transport of Chlorides]

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

F2R like thrombin or trypsin receptor 3

multiple interactions

[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP

NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472

G

FAM20C, golgi associated secretory pathway kinase

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FAM20C mRNA]

NCBI chr12:15,826,864...15,885,423
Ensembl chr12:15,826,871...15,884,543

G

Fc gamma receptor 2A

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FCGR3 mRNA]

NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967

G

ferredoxin 1

multiple interactions
increases expression

myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]

NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414

G

FIG4 phosphoinositide 5-phosphatase

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of FIG4 mRNA]

NCBI chr20:44,600,603...44,724,047
Ensembl chr20:44,600,603...44,723,844

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

[Etoposide co-treated with Cyclic AMP] results in increased expression of FOS mRNA
Cyclic AMP results in increased expression of FOS mRNA

PMID:10064622 PMID:10711420

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box M1

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA

NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684

G

forkhead box O1

multiple interactions

[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA]
FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]

PMID:26847930 PMID:31953017

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

follicle stimulating hormone subunit beta

multiple interactions
increases abundance
increases secretion

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]
FSHB protein results in increased secretion of Cyclic AMP
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]
[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]

PMID:8404651 PMID:18535249 PMID:23137853 PMID:23583632 PMID:25549949 More...

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

follicle stimulating hormone receptor

multiple interactions

[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]

NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785

G

frizzled class receptor 10

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA

NCBI chr12:28,098,371...28,101,566
Ensembl chr12:28,098,371...28,101,566

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]

PMID:22676303 PMID:26847930

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

GA binding protein transcription factor subunit beta 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GABPB1 mRNA]

NCBI chr 3:113,879,972...113,924,742
Ensembl chr 3:113,879,973...113,923,696

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

guanylate binding protein 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GBP2 mRNA]

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

glucagon

multiple interactions
increases chemical synthesis
increases abundance

[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
GCG protein results in increased chemical synthesis of Cyclic AMP
Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP]
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP

PMID:6312992 PMID:18669601 PMID:20074626 PMID:25191754 PMID:26964897

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glial cell derived neurotrophic factor

multiple interactions

3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]

PMID:19647008 PMID:33713149

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glial fibrillary acidic protein

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

growth hormone releasing hormone

multiple interactions

[GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP

NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889

G

gastric inhibitory polypeptide

multiple interactions

[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP

NCBI chr10:80,968,360...80,976,506
Ensembl chr10:80,968,352...80,976,503

G

gastric inhibitory polypeptide receptor

multiple interactions

[GIP protein binds to and results in increased activity of GIPR protein] which results in increased chemical synthesis of Cyclic AMP

NCBI chr 1:78,804,287...78,814,462
Ensembl chr 1:78,805,593...78,814,462

G

GLI family zinc finger 1

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI pathogenesis-related 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GLIPR2 mRNA]

NCBI chr 5:58,170,417...58,202,258
Ensembl chr 5:58,170,425...58,202,272

G

glucagon-like peptide 1 receptor

multiple interactions

[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP

PMID:18669601 PMID:25191754

NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241

G

G protein subunit alpha i2

multiple interactions

[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP

NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979

G

G protein subunit alpha L

multiple interactions

[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP

NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599

G

GNAS complex locus

multiple interactions

[[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP]
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP

PMID:11895442 PMID:15598656 PMID:23022524

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

G protein-coupled bile acid receptor 1

multiple interactions

[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
[Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP

PMID:17963371 PMID:23022524

NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168

G

glypican 3

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GPC3 mRNA]

NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798

G

GREB1 like retinoic acid receptor coactivator

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GREB1L mRNA]

NCBI chr18:1,392,330...1,629,483
Ensembl chr18:1,392,725...1,628,067

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor NMDA type subunit 1

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2A

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

G protein-coupled receptor kinase 2

multiple interactions

[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

granulin precursor

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GRN mRNA]

NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775

G

glycogen synthase kinase 3 beta

multiple interactions

GSK3B protein affects the reaction [Deamino Arginine Vasopressin results in increased abundance of Cyclic AMP]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

GTP binding protein 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GTPBP2 mRNA]

NCBI chr 9:14,813,964...14,823,419
Ensembl chr 9:14,813,964...14,823,241

G

glycophorin C

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of GYPC mRNA]

NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204

G

hydroxycarboxylic acid receptor 2

multiple interactions
decreases abundance

[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
HCAR2 protein results in decreased abundance of Cyclic AMP

PMID:17124637 PMID:19223991 PMID:20655299

NCBI chr12:32,726,252...32,728,238
Ensembl chr12:32,726,184...32,728,504

G

histone deacetylase 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HDAC2 mRNA]

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

histone deacetylase 6

affects abundance

HDAC6 protein affects the abundance of Cyclic AMP

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

hes family bHLH transcription factor 3

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA

NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261

G

histone cluster 2 H2B family member E

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIST2H2BE mRNA]

NCBI chr 2:183,780,583...183,783,030

G

HIVEP zinc finger 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HIVEP2 mRNA]

NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993

G

hepatocyte nuclear factor 4, alpha

multiple interactions

Cyclic AMP promotes the reaction [HNF4A protein binds to CYP2A5 promoter]

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

homeo box B1

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA

NCBI chr10:81,331,507...81,332,928
Ensembl chr10:81,331,507...81,332,836

G

haptoglobin

multiple interactions

Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]

NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523

G

histamine receptor H 1

multiple interactions

1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

histamine receptor H 2

increases abundance
multiple interactions

HRH2 protein results in increased abundance of Cyclic AMP
[Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]

PMID:9187264 PMID:9681472 PMID:15843518

NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631

G

histamine receptor H3

multiple interactions

[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

increases expression

Cyclic AMP results in increased expression of HSD3B1 mRNA

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

increases expression

Cyclic AMP results in increased expression of HSD3B2 mRNA

NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852

G

5-hydroxytryptamine receptor 1A

multiple interactions

[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

PMID:11356925 PMID:20580787

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 1B

multiple interactions

HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 6

increases abundance
multiple interactions

HTR6 protein results in increased abundance of Cyclic AMP
Serotonin promotes the reaction [HTR6 protein results in increased abundance of Cyclic AMP]

NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912

G

5-hydroxytryptamine receptor 7

increases abundance
multiple interactions

HTR7 results in increased abundance of Cyclic AMP
[3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]

PMID:10720076 PMID:14578406 PMID:19509219

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

HtrA serine peptidase 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of HTRA1 mRNA]

NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Cyclic AMP]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

indoleamine 2,3-dioxygenase 1

multiple interactions

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein

NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730

G

immediate early response 3

multiple interactions
affects response to substance

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA]
IER3 protein affects the susceptibility to Cyclic AMP
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]]

PMID:19414516 PMID:20713914

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interferon gamma

multiple interactions

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 1

multiple interactions

2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]

PMID:31953017 PMID:32446389 PMID:32781018

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 5

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IGFBP5 mRNA]

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

interleukin 12A

multiple interactions

Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

interleukin 12B

multiple interactions

Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 15 receptor subunit alpha

multiple interactions
decreases expression

[Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]

NCBI chr17:66,802,300...66,831,973
Ensembl chr17:66,802,334...66,832,278

G

interleukin 17 receptor E

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IL17RE mRNA]

NCBI chr 4:146,604,547...146,618,206
Ensembl chr 4:146,605,526...146,618,206

G

interleukin 1 beta

multiple interactions
increases abundance

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]
Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]

PMID:8904084 PMID:17709599 PMID:22117073

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

multiple interactions
increases expression

Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 4

increases chemical synthesis
multiple interactions

IL4 protein results in increased chemical synthesis of Cyclic AMP
Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

increases expression

Cyclic AMP analog results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta A

increases secretion

Cyclic AMP results in increased secretion of INHBA protein

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

inhibin subunit beta E

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

insulin 1

multiple interactions

[Theophylline co-treated with INS1 protein] results in decreased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP]
[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]

PMID:4306506 PMID:26847930

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

IQ motif containing GTPase activating protein 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IQGAP1 mRNA]

NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755

G

interferon regulatory factor 6

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IRF6 mRNA]

NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386

G

integrin subunit beta 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ITGB1 mRNA]

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Etoposide co-treated with Cyclic AMP] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily D member 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA]

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

kinesin family member 15

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KIF15 mRNA]

NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750

G

kininogen 1

increases abundance

KNG1 results in increased abundance of Cyclic AMP

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

lysosomal-associated membrane protein 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LAMP1 mRNA]

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

lymphoid enhancer binding factor 1

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

leptin

increases abundance
multiple interactions
increases expression

LEP protein results in increased abundance of Cyclic AMP
3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA]

PMID:11342529 PMID:27381457

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

multiple interactions
increases abundance
increases chemical synthesis
affects secretion

5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]
LHB protein affects the secretion of Cyclic AMP
[LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]

PMID:2153673 PMID:6430271 PMID:8404651 PMID:23071612 PMID:33638691

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions

[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]
[ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]

PMID:19766106 PMID:20378682

NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521

G

lipase E, hormone sensitive type

increases activity

Cyclic AMP results in increased activity of LIPE protein

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

lamin A/C

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LMNA mRNA]

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

leucine rich adaptor protein 1-like

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of LURAP1L mRNA]

NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438

G

mannosidase, alpha, class 1A, member 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MAN1A mRNA]

NCBI chr20:33,202,509...33,385,747
Ensembl chr20:33,202,517...33,385,824

G

microtubule-associated protein 2

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

melanocortin 2 receptor

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased expression of MC2R mRNA

NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488

G

Myb/SANT DNA binding domain containing 3

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of MSANTD3 mRNA]

NCBI chr 5:62,866,022...62,892,444
Ensembl chr 5:62,866,022...62,888,859

G

NADH:ubiquinone oxidoreductase subunit B11

increases phosphorylation
multiple interactions

Cyclic AMP results in increased phosphorylation of NDUFB11 protein
Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]

NCBI chr X:1,572,805...1,575,063
Ensembl chr X:1,572,785...1,575,062

G

nerve growth factor

multiple interactions
increases expression

[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA
Cyclic AMP results in increased expression of NGF mRNA

PMID:2174743 PMID:2853697

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

noggin

multiple interactions

NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

N-acetylneuraminate pyruvate lyase

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NPL mRNA]

NCBI chr13:65,655,099...65,697,464
Ensembl chr13:65,655,118...65,697,372

G

nuclear receptor subfamily 0, group B, member 1

decreases expression
multiple interactions

Cyclic AMP results in decreased expression of NR0B1 mRNA
Verapamil promotes the reaction [Cyclic AMP results in decreased expression of NR0B1 mRNA]

NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011

G

N-terminal asparagine amidase

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of NTAN1 mRNA]

NCBI chr10:2,111,090...2,126,119

G

ornithine aminotransferase

increases activity
multiple interactions
increases expression

Cyclic AMP results in increased activity of OAT protein
Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]

PMID:2824512 PMID:2827574

NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682

G

opioid receptor, mu 1

multiple interactions

[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

olfactory receptor family 51 subfamily A member 41

multiple interactions

[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP]

NCBI chr 1:157,454,391...157,455,398
Ensembl chr 1:157,454,041...157,456,953

G

olfactory receptor family 5 subfamily D member 18

multiple interactions

[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP

PMID:12767924 PMID:15716417

NCBI chr 3:73,516,522...73,517,463
Ensembl chr 3:73,516,364...73,519,858
Ensembl chr 3:73,516,364...73,519,858

G

olfactory receptor family 6 subfamily E member 1

multiple interactions

[citronellal results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP

NCBI chr15:27,733,881...27,734,825
Ensembl chr15:27,729,827...27,736,945

G

OS9, endoplasmic reticulum lectin

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of OS9 mRNA]

NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745

G

phosphoenolpyruvate carboxykinase 1

increases expression
multiple interactions

Cyclic AMP results in increased expression of PCK1 mRNA
[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]

PMID:2569870 PMID:8971075 PMID:10446394 PMID:22117073 PMID:22676303 More...

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

phosphodiesterase 10A

multiple interactions
increases hydrolysis

Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563

G

phosphodiesterase 11A

increases hydrolysis

PDE11A protein results in increased hydrolysis of Cyclic AMP

NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158

G

phosphodiesterase 4B

multiple interactions

[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP
[Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein]

PMID:16293762 PMID:21266552 PMID:21854221

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

phosphodiesterase 7A

multiple interactions
increases hydrolysis

1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]

PMID:10618442 PMID:10814504

NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681

G

phosphodiesterase 7B

increases hydrolysis
multiple interactions

PDE7B protein results in increased hydrolysis of Cyclic AMP
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]

PMID:10618442 PMID:10814504 PMID:10872825

NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:15,182,704...15,492,900

G

phosphodiesterase 8A

multiple interactions
increases metabolic processing
increases hydrolysis

Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]
PDE8A protein results in increased hydrolysis of Cyclic AMP
Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP]

PMID:9671792 PMID:12681444

NCBI chr 1:135,166,143...135,288,986
Ensembl chr 1:135,166,237...135,288,024

G

phosphodiesterase 8B

multiple interactions
increases metabolic processing
increases hydrolysis

9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]

PMID:9784418 PMID:12681444

NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209

G

phosphodiesterase 9A

increases hydrolysis

PDE9A protein results in increased hydrolysis of Cyclic AMP

NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948

G

pyruvate dehydrogenase kinase 1

multiple interactions
affects abundance

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]

NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038

G

phosphatidylethanolamine binding protein 1

multiple interactions

PEBP1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

profilin 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PFN2 mRNA]

NCBI chr 2:142,067,102...142,072,938
Ensembl chr 2:142,067,104...142,072,938

G

progesterone receptor

multiple interactions

Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

cAMP-dependent protein kinase inhibitor alpha

multiple interactions

[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]

NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282

G

phospholipase A2 group 4A

increases expression
multiple interactions

Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein]

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

proopiomelanocortin

multiple interactions
increases abundance

[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP]
POMC protein modified form results in increased abundance of Cyclic AMP
Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP]

PMID:4306506 PMID:26586997

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

cytochrome p450 oxidoreductase

increases expression

Cyclic AMP results in increased expression of POR mRNA

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

PPARG coactivator 1 alpha

multiple interactions
increases expression

Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]
Cyclic AMP results in increased expression of PPARGC1A mRNA

PMID:18602936 PMID:22117073 PMID:22676303

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 1, regulatory (inhibitor) subunit 14B

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of PPP1R14B mRNA]

NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319

G

protein kinase cAMP-activated catalytic subunit beta

multiple interactions
affects response to substance

[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]

NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198

G

protein kinase cAMP-dependent type I regulatory subunit alpha

multiple interactions

[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]

NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041

G

protein kinase cAMP-dependent type II regulatory subunit alpha

multiple interactions

Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2A protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein]

NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628

G

protein kinase cAMP-dependent type II regulatory subunit beta

multiple interactions

Clozapine inhibits the reaction [Cyclic AMP binds to PRKAR2B protein]; Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein]

NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933

G

prolactin

multiple interactions
increases secretion

[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]
Cyclic AMP results in increased secretion of PRL protein

PMID:20074812 PMID:23022511 PMID:31953017 PMID:32446389 PMID:32781018

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prokineticin 1

affects response to substance

PROK1 protein affects the susceptibility to Cyclic AMP

NCBI chr 2:194,850,539...194,859,343
Ensembl chr 2:194,853,991...194,859,250

G

prostaglandin D2 receptor 2

multiple interactions

[5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP

NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213

G

prostaglandin E receptor 2

multiple interactions

[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP]

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714

G

prostaglandin E receptor 3

multiple interactions

[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP

NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434

G

prostaglandin E receptor 4

multiple interactions

[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP]

NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670

G

prostaglandin I2 receptor

multiple interactions

[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP]

NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

parathyroid hormone

increases abundance

PTH protein results in increased abundance of Cyclic AMP

NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530

G

parathyroid hormone-like hormone

increases abundance

PTHLH protein results in increased abundance of Cyclic AMP

NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847

G

prothymosin alpha

increases abundance

PTMA protein results in increased abundance of Cyclic AMP

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

RAB3B, member RAS oncogene family

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RAB3B mRNA]

NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401

G

ral guanine nucleotide dissociation stimulator like 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RGL1 mRNA]

NCBI chr13:64,634,489...64,904,170
Ensembl chr13:64,635,246...64,904,191

G

RAP1A, member of RAS oncogene family

increases activity

Cyclic AMP results in increased activity of RAP1A protein

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

RAP1B, member of RAS oncogene family

multiple interactions

[Pentoxifylline results in increased abundance of Cyclic AMP] results in increased abundance of [RAP1B protein binds to Guanosine Triphosphate]

NCBI chr 7:53,423,039...53,456,349
Ensembl chr 7:53,423,130...53,456,370

G

RNA binding fox-1 homolog 3

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein

NCBI chr10:103,720,355...104,157,277
Ensembl chr10:103,720,636...104,156,935

G

RNA binding motif protein 12

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RBM12 mRNA]

NCBI chr 3:144,609,661...144,629,911
Ensembl chr 3:144,611,623...144,629,915
Ensembl chr 3:144,611,623...144,629,915

G

regulator of microtubule dynamics 3

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of RMDN3 mRNA]

NCBI chr 3:106,125,961...106,146,568
Ensembl chr 3:106,125,951...106,146,586

G

S100 calcium binding protein B

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

sodium voltage-gated channel alpha subunit 2

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA

NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214

G

secretin

multiple interactions
increases abundance

Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP]

NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658

G

syndecan 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SDC1 mRNA]

NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264

G

solute carrier family 17 member 6

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA

NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542

G

solute carrier family 17 member 7

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein

NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588

G

solute carrier family 22 member 8

affects transport

SLC22A8 protein affects the transport of Cyclic AMP

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 2 member 5

affects expression
multiple interactions

Cyclic AMP affects the expression of SLC2A5 mRNA
[[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein
[Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA

PMID:8037665 PMID:8554516 PMID:12820898

NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106

G

solute carrier family 4 member 2

multiple interactions

Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]

NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965

G

SPARC related modular calcium binding 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SMOC2 mRNA]

NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693

G

sorting nexin 33

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of SNX33 mRNA]

NCBI chr 8:57,315,861...57,328,522
Ensembl chr 8:57,317,161...57,327,538

G

suppressor of cytokine signaling 3

multiple interactions

2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 2

multiple interactions

WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

steroid 5 alpha-reductase 1

increases expression

Cyclic AMP results in increased expression of SRD5A1 mRNA

NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461

G

somatostatin

multiple interactions

[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]

NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173

G

somatostatin receptor 2

multiple interactions

[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]

NCBI chr10:98,664,204...98,671,370
Ensembl chr10:98,664,216...98,674,351

G

ST6 beta-galactoside alpha-2,6-sialyltransferase 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of ST6GAL2 mRNA]

NCBI chr 9:9,181,744...9,274,161
Ensembl chr 9:9,182,399...9,269,697

G

steroidogenic acute regulatory protein

multiple interactions
increases expression

[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein]
Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein

PMID:19822634 PMID:20100736 PMID:25576683 PMID:28668616

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

trace-amine-associated receptor 1

multiple interactions

[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

taste 1 receptor member 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAS1R2 mRNA]

NCBI chr 5:151,909,617...151,925,760
Ensembl chr 5:151,830,701...151,925,345

G

Tax1 binding protein 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TAX1BP1 mRNA]

NCBI chr 4:81,821,991...81,877,906
Ensembl chr 4:81,821,989...81,879,100

G

tryptophan 2,3-dioxygenase

multiple interactions

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA

NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511

G

telomerase reverse transcriptase

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

testis expressed 14, intercellular bridge forming factor

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TEX14 mRNA]

NCBI chr10:72,231,766...72,356,938
Ensembl chr10:72,231,801...72,355,805

G

trefoil factor 1

multiple interactions
increases expression

CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter]

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

transforming growth factor, beta 3

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

thymosin beta 15B2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMSB15B2 mRNA]

NCBI chr X:100,298,705...100,300,820
Ensembl chr X:100,298,514...100,300,886

G

transmembrane O-mannosyltransferase targeting cadherins 4

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TMTC4 mRNA]

NCBI chr15:100,000,157...100,056,573
Ensembl chr15:100,000,152...100,056,543

G

tumor necrosis factor

decreases expression
multiple interactions

Cyclic AMP results in decreased expression of TNF protein
Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

PMID:8550079 PMID:21266552 PMID:23566200

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 12

decreases expression

Cyclic AMP results in decreased expression of TNFSF12 mRNA

NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213

G

transient receptor potential cation channel, subfamily V, member 4

increases expression
multiple interactions

Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein]

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

thyroid stimulating hormone subunit beta

multiple interactions
increases abundance

[Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]]

PMID:19766106 PMID:21072367 PMID:21123444

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

thyroid stimulating hormone receptor

multiple interactions
increases abundance

[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]]

PMID:19766106 PMID:21123444

NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538

G

tetratricopeptide repeat domain 6

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of TTC6 mRNA]

NCBI chr 6:75,136,827...75,368,176
Ensembl chr 6:75,136,792...75,368,178

G

tubulin, beta 3 class III

multiple interactions

[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

G

ubiquitin-like modifier activating enzyme 5

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of UBA5 mRNA]

NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894

G

vasohibin 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH1 mRNA]

NCBI chr 6:106,330,374...106,345,740
Ensembl chr 6:106,329,123...106,345,726

G

vasohibin 2

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VASH2 mRNA]

NCBI chr13:102,529,718...102,561,204
Ensembl chr13:102,529,719...102,560,391

G

vesicle amine transport 1

multiple interactions

2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of VAT1 mRNA]

NCBI chr10:86,389,549...86,397,167
Ensembl chr10:86,389,545...86,397,224

G

vascular endothelial growth factor A

multiple interactions

Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vasoactive intestinal peptide

multiple interactions
increases abundance

[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP
alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]
VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP

PMID:1657658 PMID:2467674 PMID:7733904 PMID:20732086

NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216

G

vasoactive intestinal peptide receptor 2

multiple interactions

[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP

NCBI chr 6:136,996,664...137,070,599
Ensembl chr 6:137,001,511...137,070,597

G

Wnt family member 5A

multiple interactions

WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP]

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

zinc finger protein 36, C3H type-like 2

increases abundance

ZFP36L2 protein mutant form results in increased abundance of Cyclic AMP

NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064

3',5'-cyclic GMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases export
increases transport
multiple interactions

ABCC4 protein results in increased export of Cyclic GMP
ABCC4 protein results in increased transport of Cyclic GMP
daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]

PMID:11856762 PMID:16156793

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

angiotensinogen

multiple interactions
increases abundance

AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]
AGT protein modified form results in increased abundance of Cyclic GMP

PMID:11696475 PMID:28299329

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 2

multiple interactions

[PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

AKT serine/threonine kinase 1

multiple interactions

AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Cyclic GMP]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 2 family member

multiple interactions

ALDH2 protein affects the reaction [Nitroglycerin results in decreased abundance of Cyclic GMP]

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

apolipoprotein E

decreases abundance

APOE gene mutant form results in decreased abundance of Cyclic GMP

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

bradykinin receptor B1

multiple interactions

[bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

multiple interactions

[icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

caspase 3

multiple interactions

Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

chaperonin containing TCP1 subunit 7

multiple interactions

CCT7 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP]

NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580

G

endothelin 1

multiple interactions
increases abundance

Puromycin Aminonucleoside inhibits the reaction [EDN1 protein results in increased abundance of Cyclic GMP]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin 3

multiple interactions
increases abundance

Puromycin Aminonucleoside promotes the reaction [EDN3 protein results in increased abundance of Cyclic GMP]

NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093

G

erythropoietin

multiple interactions

EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP]

PMID:25041251 PMID:25490417

NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946

G

GTP cyclohydrolase 1

affects abundance
increases abundance
multiple interactions

GCH1 protein affects the abundance of Cyclic GMP
GCH1 gene mutant form results in increased abundance of Cyclic GMP
CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]

PMID:21963838 PMID:25490417

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

gonadotropin releasing hormone 1

multiple interactions

[manganese chloride results in increased chemical synthesis of Cyclic GMP] which results in increased secretion of GNRH1 protein

PMID:17110411 PMID:17290048

NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

guanylate cyclase 1 soluble subunit alpha 1

multiple interactions
increases abundance

[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP]
GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP

PMID:22171090 PMID:24213632 PMID:25373139

NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671

G

guanylate cyclase 1 soluble subunit beta 1

multiple interactions

[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP

NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916

G

heme oxygenase 2

affects abundance

HMOX2 affects the abundance of Cyclic GMP

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

interleukin 12 receptor subunit beta 2

increases expression

Cyclic GMP results in increased expression of IL12RB2 mRNA

NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289

G

interleukin 1 beta

multiple interactions
increases abundance

Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP]

PMID:11506125 PMID:14762100

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

mitogen activated protein kinase kinase 1

multiple interactions
decreases phosphorylation

Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]
Cyclic GMP results in decreased phosphorylation of MAP2K1 protein

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

decreases phosphorylation
multiple interactions

Cyclic GMP results in decreased phosphorylation of MAP2K2 protein
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen-activated protein kinase 8

increases activity

Cyclic GMP analog results in increased activity of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

nitric oxide synthase 2

multiple interactions

[testosterone enanthate results in increased expression of NOS2 mRNA] which results in increased abundance of Cyclic GMP

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
increases abundance

NOS3 protein affects the reaction [Ramipril results in increased abundance of Cyclic GMP]
NOS3 protein results in increased abundance of Cyclic GMP

PMID:11504159 PMID:16891913

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

natriuretic peptide A

multiple interactions
increases abundance

Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
NPPA protein results in increased abundance of Cyclic GMP
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]

PMID:9421401 PMID:11696475 PMID:12022755 PMID:12582005 PMID:12972712 More...

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide C

increases chemical synthesis
increases abundance
multiple interactions

NPPC protein results in increased chemical synthesis of Cyclic GMP
NPPC protein results in increased abundance of Cyclic GMP
Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP]

PMID:17629948 PMID:18222015

NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251

G

phosphodiesterase 10A

multiple interactions
increases hydrolysis

Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563

G

phosphodiesterase 11A

multiple interactions
increases hydrolysis

1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]

NCBI chr 3:60,913,562...61,297,154
Ensembl chr 3:60,913,562...61,297,158

G

phosphodiesterase 1A

multiple interactions

PDE1A protein inhibits the reaction [Nitroglycerin results in increased abundance of Cyclic GMP]

NCBI chr 3:64,745,140...65,025,178
Ensembl chr 3:64,747,269...65,024,874

G

phosphodiesterase 5A

decreases abundance

PDE5A protein results in decreased abundance of Cyclic GMP

NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701

G

phosphodiesterase 9A

increases hydrolysis
multiple interactions

PDE9A protein results in increased hydrolysis of Cyclic GMP
zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP]

NCBI chr20:9,469,809...9,562,949
Ensembl chr20:9,469,848...9,562,948

G

proopiomelanocortin

affects abundance

POMC protein affects the abundance of Cyclic GMP

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

protein tyrosine phosphatase, non-receptor type 12

increases activity

Cyclic GMP results in increased activity of PTPN12 protein

NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927

G

serine/threonine kinase 11

multiple interactions

STK11 protein promotes the reaction [Histamine results in increased abundance of Cyclic GMP]

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

tumor necrosis factor

multiple interactions
decreases abundance

7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions
increases abundance

N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vimentin

multiple interactions

VIM protein affects the susceptibility to [Acetylcholine co-treated with Cyclic GMP co-treated with Indomethacin]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

xanthine dehydrogenase

multiple interactions

[Xanthine co-treated with XDH protein] inhibits the reaction [Nitroprusside results in increased abundance of Cyclic GMP]

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

3'-CMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CDP-diacylglycerol--inositol 3-phosphatidyltransferase

multiple interactions

[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate

NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408

3'-phospho-5'-adenylyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

N-acetyltransferase 2

multiple interactions

[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

purinergic receptor P2Y1

decreases activity

Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein

NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457

G

sulfotransferase family 1A member 1

multiple interactions
increases sulfation

2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]
SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate

PMID:11425650 PMID:16601080 PMID:20545351

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

sulfotransferase family 2A member 1

multiple interactions

[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol]

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

3-phosphoglyceric acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-phosphoglycerate]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

microtubule-associated protein tau

multiple interactions

[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of 3-phosphoglycerate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of 3-phosphoglycerate]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

7-methyl-7,8-dihydroguanosine-5'-diphosphate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

eukaryotic translation initiation factor 4E

affects binding
multiple interactions

7-methylguanosine 5'-diphosphate analog binds to EIF4E protein
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

7-methyl-GTP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

eukaryotic translation initiation factor 4E

multiple interactions

7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein]

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions
affects binding

1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

eukaryotic translation initiation factor 4 gamma 1

multiple interactions
affects binding

1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]

NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941

8-(4-chlorophenylthio)-cAMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCB1A mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 2

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 2

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

AKT serine/threonine kinase 1

increases phosphorylation

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

Bcl2-like 11

increases expression
increases response to substance

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein
BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

caspase 3

increases activity

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cofilin 1

decreases phosphorylation

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased phosphorylation of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

CF transmembrane conductance regulator

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

cAMP responsive element binding protein 1

multiple interactions
increases phosphorylation

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein

PMID:14741741 PMID:20610540

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

NFE2 like bZIP transcription factor 2

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear receptor subfamily 1, group H, member 2

multiple interactions

NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]

NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 2

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of NR1I3 mRNA

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

poly (ADP-ribose) polymerase 1

multiple interactions

[Acetylcysteine results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] which results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

ras homolog family member A

multiple interactions
decreases activity

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

rhotekin

multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein]

NCBI chr 4:115,640,813...115,657,952
Ensembl chr 4:115,640,774...115,657,952

G

sodium channel epithelial 1 subunit alpha

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]

NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181

G

sodium channel epithelial 1 subunit beta

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]

NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451

G

sodium channel epithelial 1 subunit gamma

multiple interactions

[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]

NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816

G

solute carrier family 10 member 1

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier organic anion transporter family, member 1a4

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1A4 mRNA

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of SLCO1B2 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

synaptosome associated protein 25

multiple interactions
affects splicing

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon]

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP promotes the reaction [Capsaicin results in increased activity of TRPV1]

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

G

vasoactive intestinal peptide

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of VIP mRNA

NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216

8-(4-chlorophenylthio)-cGMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 15-lipoxygenase

increases expression

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

Rho guanine nucleotide exchange factor 17

multiple interactions

2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]

NCBI chr 1:155,230,607...155,290,163
Ensembl chr 1:155,233,168...155,290,498

G

CCAAT/enhancer binding protein beta

increases expression
multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein]

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

fatty acid binding protein 4

increases expression
multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein]

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

natriuretic peptide A

multiple interactions

[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase cGMP-dependent 1

multiple interactions
decreases expression
increases activity

2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]

PMID:9366573 PMID:11799084 PMID:23195829

NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080

G

ras homolog family member A

multiple interactions

[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

sodium channel epithelial 1 subunit alpha

multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]

NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181

G

sodium channel epithelial 1 subunit beta

multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]

NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451

G

sodium channel epithelial 1 subunit gamma

multiple interactions

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of [SCNN1A binds to SCNN1B binds to SCNN1G binds to SCNN1D]

NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816

G

serum response factor

multiple interactions

[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein

NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733

G

vasodilator-stimulated phosphoprotein

increases phosphorylation
decreases phosphorylation

8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein

PMID:11799084 PMID:16166323

NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061

8-Br-cAMP

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABCA1 protein

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily D member 2

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCD2 mRNA

NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642

G

ATP binding cassette subfamily G member 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

multiple interactions

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

actin-binding LIM protein 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ABLIM1 mRNA

NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969

G

actin binding LIM protein family, member 2

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ABLIM2 mRNA

NCBI chr14:74,865,409...74,990,334
Ensembl chr14:74,866,281...74,990,334

G

acetyl-CoA acetyltransferase 2

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

angiotensin converting enzyme 2

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acid phosphatase 3

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ACP3 mRNA

NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADAMTS6 mRNA

PMID:20147733 PMID:22079614

NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298

G

ADAM metallopeptidase with thrombospondin type 1 motif, 8

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADAMTS8 mRNA

NCBI chr 8:29,349,078...29,368,413
Ensembl chr 8:29,349,114...29,368,404

G

adenylate cyclase 7

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADCY7 mRNA

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311

G

adhesion G protein-coupled receptor D1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRD1 mRNA

NCBI chr12:27,488,908...27,603,714
Ensembl chr12:27,488,908...27,603,696

G

adhesion G protein-coupled receptor F5

multiple interactions

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA

NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968

G

adhesion G protein-coupled receptor G1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

adhesion G protein-coupled receptor G2

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADGRG2 mRNA

NCBI chr X:34,297,402...34,422,590
Ensembl chr X:34,297,402...34,422,609

G

adrenoceptor alpha 2A

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

anterior gradient 2, protein disulphide isomerase family member

multiple interactions

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA

NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371

G

angiotensinogen

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGT mRNA

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AGTR1 mRNA

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

aryl hydrocarbon receptor

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

apoptosis inducing factor, mitochondria associated 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AIFM1 mRNA

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

A-kinase anchoring protein 7

multiple interactions

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA

NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797

G

A-kinase anchoring protein 9

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKAP9 mRNA

NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606

G

AKT serine/threonine kinase 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

angiopoietin 1

multiple interactions

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

angiopoietin-like 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ANGPTL1 mRNA

NCBI chr13:68,963,186...68,981,649
Ensembl chr13:68,962,991...68,992,570

G

ANKH inorganic pyrophosphate transport regulator

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ANKH mRNA

NCBI chr 2:78,153,027...78,280,181
Ensembl chr 2:78,153,026...78,280,187

G

annexin A8

multiple interactions

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA

NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043

G

aminopeptidase O

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AOPEP mRNA

NCBI chr17:1,811,281...2,127,316
Ensembl chr17:1,811,980...2,127,331

G

apoptotic peptidase activating factor 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amyloid beta precursor protein binding family B member 1 interacting protein

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of APBB1IP mRNA

NCBI chr17:84,941,404...85,033,020
Ensembl chr17:84,982,243...85,033,010

G

APC regulator of WNT signaling pathway

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APC mRNA

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

APC down-regulated 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of APCDD1 mRNA

NCBI chr18:56,385,398...56,416,065
Ensembl chr18:56,385,264...56,416,070

G

androgen receptor

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AREG mRNA

PMID:20147733 PMID:22079614

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

Rho/Rac guanine nucleotide exchange factor 2

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARHGEF2 mRNA

NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355

G

Rho guanine nucleotide exchange factor 4

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARHGEF4 mRNA

NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075

G

AT-rich interaction domain 5B

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ARID5B mRNA

NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433

G

armadillo repeat containing, X-linked 3

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX3 mRNA

NCBI chr X:97,937,115...97,942,098
Ensembl chr X:97,936,999...97,942,098

G

armadillo repeat containing, X-linked 4

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ARMCX4 mRNA

NCBI chr X:97,860,526...97,870,912
Ensembl chr X:97,860,629...97,870,912

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

ATPase H+/K+ transporting subunit alpha

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ATP4A mRNA

NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844

G

arginine vasopressin-induced 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of AVPI1 mRNA

NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154

G

beta-1,4-N-acetyl-galactosaminyl transferase 3

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of B4GALNT3 mRNA

NCBI chr 4:153,409,019...153,509,019
Ensembl chr 4:153,409,004...153,509,321

G

B-cell scaffold protein with ankyrin repeats 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BANK1 mRNA

NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein

PMID:11802967 PMID:16709600

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

branched chain amino acid transaminase 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BCAT1 mRNA

NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597

G

BCL2, apoptosis regulator

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BCL2

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions

[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BCL2L11 protein

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

bradykinin receptor B1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB1 mRNA

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BDKRB2 mRNA

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

bone morphogenetic protein 4

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

bone morphogenetic protein 6

decreases expression
increases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of BMP6 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BMP6 mRNA

PMID:20147733 PMID:22079614

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

BMP/retinoic acid inducible neural specific 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BRINP1 mRNA

NCBI chr 5:82,348,501...82,550,506
Ensembl chr 5:82,348,930...82,493,150

G

BTB domain containing 9

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BTBD9 mRNA

NCBI chr20:8,286,337...8,645,567
Ensembl chr20:8,288,711...8,643,960

G

Cdk5 and Abl enzyme substrate 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABLES1 mRNA

NCBI chr18:3,076,556...3,181,181
Ensembl chr18:3,075,524...3,181,181

G

calcium binding protein 7

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CABP7 mRNA

NCBI chr14:79,598,822...79,609,172
Ensembl chr14:79,598,827...79,609,240

G

cell adhesion molecule 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CADM1 mRNA

NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833

G

cell adhesion molecule 2

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CADM2 mRNA

NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400

G

calneuron 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CALN1 mRNA

NCBI chr12:25,811,743...26,303,670
Ensembl chr12:25,819,628...26,303,344

G

calreticulin

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAMK2N1 mRNA

NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600

G

calpain 15

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CAPN15 mRNA

NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508

G

calpain 2

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN2 mRNA

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

calpain 6

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CAPN6 mRNA

NCBI chr X:107,380,774...107,405,489
Ensembl chr X:107,380,774...107,405,489

G

caspase recruitment domain family, member 14

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARD14 mRNA

NCBI chr10:104,572,059...104,601,606
Ensembl chr10:104,566,424...104,601,905

G

cysteinyl-tRNA synthetase 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CARS1 mRNA

NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941

G

caspase 3

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CASP3 mRNA

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CASP9 mRNA

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

carbonyl reductase 4

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CBR4 mRNA

NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712

G

coiled-coil domain containing 170

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC170 mRNA

NCBI chr 1:40,945,607...41,050,010
Ensembl chr 1:40,945,961...41,085,040

G

coiled-coil domain containing 3

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCDC3 mRNA

NCBI chr17:73,031,891...73,135,173
Ensembl chr17:73,035,045...73,135,337

G

coiled-coil domain containing 80

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCDC80 mRNA

NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein

PMID:11230753 PMID:16997883 PMID:20940016

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 3

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN3 mRNA

NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019

G

cellular communication network factor 6

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCN6 mRNA

NCBI chr20:42,569,309...42,585,126
Ensembl chr20:42,569,309...42,585,126

G

cyclin A1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCNA1 mRNA

NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157

G

cyclin D2

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

CD244 molecule

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD244 mRNA

NCBI chr13:84,051,339...84,082,864
Ensembl chr13:84,052,493...84,074,492

G

CD74 molecule

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

CD9 molecule

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CD9 mRNA

NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222

G

cell division cycle 42

multiple interactions

8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cadherin 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 22

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH22 mRNA

NCBI chr 3:153,845,563...153,970,630
Ensembl chr 3:153,845,787...153,970,588

G

cadherin 4

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDH4 mRNA

NCBI chr 3:166,525,092...167,003,380
Ensembl chr 3:166,525,099...167,003,371

G

cadherin 6

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDH6 mRNA

NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228

G

cyclin dependent kinase 2

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDK2 mRNA

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cell adhesion associated, oncogene regulated

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CDON mRNA

NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033

G

caudal type homeo box 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CDX1 mRNA

NCBI chr18:54,472,587...54,490,913
Ensembl chr18:54,473,444...54,490,814

G

CEA cell adhesion molecule 6

multiple interactions

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA

NCBI chr 1:80,416,531...80,434,668
Ensembl chr 1:80,416,531...80,434,668

G

CCAAT/enhancer binding protein gamma

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CEBPG mRNA

NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CFLAR protein alternative form

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

glycoprotein hormones, alpha polypeptide

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGA mRNA

PMID:8404651 PMID:21467749 PMID:22079614

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

cingulin

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CGN mRNA

NCBI chr 2:182,308,389...182,335,747
Ensembl chr 2:182,308,714...182,334,645

G

chimerin 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CHN1 mRNA

NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490

G

calcineurin-like EF-hand protein 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CHP1 mRNA

NCBI chr 3:106,536,009...106,571,255
Ensembl chr 3:106,536,004...106,571,251

G

cell death-inducing DFFA-like effector a

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEA mRNA

NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481

G

cell death-inducing DFFA-like effector c

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CIDEC protein

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

creatine kinase, mitochondrial 2

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CKMT2 mRNA

NCBI chr 2:23,079,918...23,110,518
Ensembl chr 2:23,079,918...23,110,430

G

claudin 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 5

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLDN5 mRNA

NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992

G

calmegin

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLGN mRNA

PMID:20147733 PMID:22079614

NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758

G

chloride intracellular channel 3

multiple interactions
increases expression

[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA

PMID:16997883 PMID:22079614

NCBI chr 3:8,271,416...8,274,023
Ensembl chr 3:8,272,097...8,274,018

G

chemerin chemokine-like receptor 1

increases expression

8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CMKLR1 mRNA

NCBI chr12:42,974,462...43,027,321
Ensembl chr12:42,974,410...43,028,129

G

cornichon family AMPA receptor auxiliary protein 3

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNIH3 mRNA

NCBI chr13:93,016,707...93,208,168
Ensembl chr13:93,099,784...93,208,121

G

cannabinoid receptor 1

decreases expression

8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of CNR1 mRNA

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099